Lafutidine API Powder

Lafutidine API Powder Chemical Identity CAS Number: 118288-08-7 Molecular Formula: C22H29N3O4S Molecular Weight: 431.55 g/mol Synonyms: Stogar, Protecadin, FRG-8813 IUPAC Name: 2-(furan-2-ylmethylsulfinyl)-N-[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide Appearance: White to off-white crystalline powder Melting Point: 92.7-94.9°C Solubility: Soluble in DMSO, ethanol, and glacial acetic acid; insoluble in water Density: 1.252 g/cm³ Boiling Point: Approximately 704.2°C at 760 mmHg Storage Conditions: Store in a sealed container, in a dry place, away from moisture and direct sunlight. Recommended storage temperature is below -20°C. Pharmacological Properties Lafutidine is a second-generation histamine H₂ receptor antagonist with a unique mechanism of action. Unlike traditional H₂ blockers, it not only inhibits gastric acid secretion but also exerts gastroprotective effects. These effects are mediated through the stimulation of calcitonin gene-related peptide (CGRP) and nitric oxide (NO), which enhance mucosal blood flow, increase mucus secretion, and promote mucosal repair. This dual action makes Lafutidine effective in treating various gastrointestinal disorders. Applications Therapeutic Use: Lafutidine is primarily used in the treatment of peptic ulcers, gastroesophageal reflux disease (GERD), and other acid-related gastrointestinal disorders. Its ability to reduce gastric acid secretion and protect the gastric mucosa makes it a valuable therapeutic agent. Pharmaceutical Manufacturing: As an active pharmaceutical ingredient (API), Lafutidine is utilized in the formulation of oral dosage forms, including tablets and capsules, for the treatment of acid-related gastrointestinal conditions. Precautions and Safety Information Handling: Avoid inhalation of dust and contact with skin and eyes. Use appropriate personal protective equipment, including gloves and safety goggles, when handling Lafutidine powder. Storage: Store in a cool, dry place, away from moisture and direct sunlight. Ensure containers are tightly sealed to prevent contamination. Disposal: Dispose of Lafutidine waste material in accordance with local environmental regulations. Regulatory Status Lafutidine is approved for use in several countries, including Japan, South Korea, and India. It is manufactured under Good Manufacturing Practice (GMP) conditions to ensure quality and consistency. Suppliers provide detailed Certificates of Analysis (CoA) and Material Safety Data Sheets (MSDS) to comply with regulatory requirements. Conclusion Lafutidine is a potent and effective H₂ receptor antagonist with additional gastroprotective properties, making it a valuable API in the treatment of acid-related gastrointestinal disorders. Its unique mechanism of action, coupled with its safety profile, positions it as a preferred choice in therapeutic applications. Note: This product is intended for use in pharmaceutical manufacturing and research and development purposes. It should be handled by qualified professionals in accordance with safety guidelines and regulatory standards. About the Company GST Registration Date: 2024 Legal Status of Firm: Partnership Number of Employees: 11 To 25 People Annual Turnover: 0 - 40 L